Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data

Gouji Toyokawa  Takashi Seto

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

Introduction

Lung cancer is the leading cause of cancer death in most countries. Although lung cancer is a highly malignant neoplasm with a poor prognosis, the molecular biological pathogenesis of lung cancer has been gradually elucidated. In particular, oncogenic drivers, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ret proto-oncogene (RET), c-ros oncogene 1, receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase, receptor, type 1 (NTRK1) have been identified [1–4]. Furthermore, they have attracted much attention as being specifically targetable by kinase inhibitors, such as gefitinib for EGFR-mutated non-small cell lung cancer (NSCLC) and crizotinib for ALK-rearranged NSCLC [5, 6]. It is therefore crucial to precisely examine these genetic disorders when treating lung cancer patients.

ALK rearrangement is a potent oncogene in NSCLC, and it fuses with several partners, including EML4, HIP1, and TPR, resulting in a potent transforming activity in NSCLC [2, 7, 8]. ALK rearrangement accounts for approximately 5% of driver oncogenes in NSCLC, and the representative clinicopathological characteristics in patients with ALK+ NSCLC are as follows: a younger age, light- or non-smoker, adenocarcinoma histology, no definite racial differences in the frequency of the ALK rearrangement, and mutually exclusive with other driver oncogenes [2, 9]. The partners which fuse with ALK contain the coiled coil domain, which is dispensable for the constitutive oligomerization of the fusion protein in cells, resulting in increased oncogenicity via the aberrant activation of downstream signaling, such as the Ras/MAPK, PI3K/AKT, and JAK/STAT pathways [2, 10].

Pre-clinical and clinical data demonstrated that patients with ALK+ NSCLC can be successfully treated with ALK inhibitors such as crizotinib, alectinib, and ceritinib. Crizotinib is a first-in-class ALK tyrosine kinase inhibitor and has been shown to be potent in ALK+ NSCLC patients, with tolerable toxicities [11, 12].
more, 2 randomized phase III trials demonstrated the superiority of crizotinib to standard chemotherapy in both first- and second-line settings [6, 13]. In addition to crizotinib, next-generation ALK inhibitors, such as alectinib and ceritinib, have been developed, and their efficacy in ALK+ lung cancer has been demonstrated [14, 15]. More importantly, both alectinib and ceritinib harbor anti-tumor activity in crizotinib-resistant ALK+ NSCLC [15, 16].

Despite the excellent efficacy of ALK inhibitors in patients with ALK+ lung cancer, resistance to ALK inhibitors is a major concern when treating ALK+ NSCLC patients. The mechanisms of resistance to ALK inhibitors can be divided into 2 types: ALK dominant or ALK non-dominant [17]. ALK dominant resistance mechanisms include secondary mutations and copy number gain (CNG) in the ALK gene; ALK non-dominant resistance mechanisms include the activation of bypass tracks, such as EGFR, Kirsten rat sarcoma viral oncogene homolog (KRAS), v-kit Hardy-Zucker-man 4 feline sarcoma viral oncogene homolog (KIT), met proto-oncogene (MET), and insulin-like growth factor 1 receptor (IGF-1R). Furthermore, treatment strategies to overcome the resistance mechanisms to ALK inhibitors have been proposed, and next-generation ALK inhibitors, agents which inhibit the bypass tracks, and heat shock protein 90 (HPS90) inhibitors are thought to be promising [18].

Therefore, both clinical and pre-clinical evidences on the resistance mechanisms to ALK inhibitors and treatment strategies to overcome the resistance have been gradually obtained. We herein concisely review the current clinical and pre-clinical data regarding the mechanisms of resistance to ALK inhibitors and the treatment strategies to overcome such resistance.

**ALK Inhibitors**

**Crizotinib**

Crizotinib was originally developed as a c-MET inhibitor, and it was later found to inhibit ALK [19, 20]. In the expanded cohort of the PROFILE1001 trial, 143 lung cancer patients with ALK rearrangement were treated with crizotinib, and the response rate and progression-free survival (PFS) were 60.8% (95% confidence interval (CI) 52.3–68.9) and 9.7 months (95% CI 7.7–12.8), respectively [12]. Although the overall survival (OS) data were immature, the estimated OS at 6 and 12 months was as high as 87.9% (95% CI 81.3–92.3) and 74.8% (95% CI 66.4–81.5), respectively. Furthermore, the PROFILE1007 trial was conducted to compare crizotinib with chemotherapy (pemetrexed or docetaxel) in ALK+ patients previously treated with platinum-based chemotherapy [6]. 347 patients with ALK+ lung cancer were enrolled in the study, and 173 and 174 patients were randomized into groups receiving crizotinib and chemotherapy, respectively. PFS achieved by crizotinib was significantly longer than that achieved by chemotherapy (7.7 vs. 3.0 months, respectively; hazard ratio (HR) for progression or death with crizotinib 0.49, 95% CI 0.37–0.64, p < 0.001). The objective response rates in the 2 arms were 65% (95% CI 58–72) and 20% (95% CI 14–26), respectively (p < 0.001). No significant differences were observed in the OS between crizotinib and chemotherapy (20.3 and 22.8 months, respectively), possibly due to the small number of events noted during the follow-up period and the crossover in patients treated with chemotherapy to crizotinib as part of a separate study.

The results from PROFILE1014, a randomized phase III trial which compared the first-line use of crizotinib with cisplatin or carboplatin plus pemetrexed, were recently published [13]. 172 and 171 patients were assigned to the crizotinib and chemotherapy groups, respectively. PFS, which was a primary endpoint, was 10.9 and 7.0 months (HR for progression or death with crizotinib, 0.45, 95% CI 0.35–0.60, p < 0.001), respectively, with the response rates in both arms being 74 and 45%, respectively. Similar to PROFILE1007, median OS was not reached, and the probability of 1-year survival in the crizotinib and chemotherapy groups was 84 and 79% (HR for death with crizotinib, 0.82, 95% CI 0.54–1.26, p = 0.36), respectively. Thus, crizotinib was established as first- and second-line treatment for ALK+ lung cancer.

**Second-Generation ALK Inhibitors**

Several second-generation ALK inhibitors have been developed and are currently under evaluation in clinical trials. Alectinib (CHS5424802) is a very selective inhibitor of ALK as well as RET [21, 22], and the AF-001JP trial investigating the safety and efficacy of alectinib was conducted in Japan [14]. 46 lung cancer ALK-inhibitor-naïve patients with the ALK rearrangement, which was identified by both fluorescence in situ hybridization and immunohistochemistry or reverse transcription polymerase chain reaction, were treated with 300 mg alectinib twice daily. Intriguingly, the objective response rate and PFS were as high and long as 93.5% (95% CI 66.4–81.5) and 27.7 months (95% CI 26.9–not evaluable), respectively. With regard to ceritinib, among 114 ALK+ lung cancer patients treated with at least 400 mg of ceritinib per day, objective response rate and PFS were as high as 93.5% (95% CI 48–67) and 7.0 months (95% CI 5.6–9.3), respectively [15]. 34 ceritinib-naïve and 80 crizotinib-treated patients achieved response rates of 62 and 56%, respectively. Intriguingly, ceritinib was active even when the resistance mechanism was unknown. Very importantly, both alectinib and ceritinib have been shown to be effective for ceritinib-resistant patients, with response rates of 55 and 56%, respectively [15, 16]. In addition to these agents, several ALK inhibitors, such as AP26133, ASP3062, X-396, and PF-06463922, are currently under evaluation in clinical trials. Alectinib has been shown to have antitumor activity in crizotinib-resistant ALK+ lung cancer patients who are successfully over in patients treated with chemotherapy to crizotinib as part of a separate study.

**Resistance Mechanisms to ALK Inhibitors**

Almost all ALK+ lung cancer patients who are successfully treated with ALK inhibitors experience resistance to the inhibitors, and this resistance is therefore the most crucial issue to resolve. As
Camidge and Doebele [17] previously described, the mechanisms of resistance to ALK inhibitors can be divided into 2 groups: ALK dominant, which means 'still harboring addiction to ALK signaling' or ALK non-dominant, which means 'activation of bypass tracks'. ALK dominant mechanisms include secondary mutations in the ALK gene and CNG, and ALK non-dominant mechanisms include the activation of EGFR, KRAS, KIT, MET, and IGF-1R pathways. The frequency of ALK dominant resistance mechanisms to crizotinib is 50%: secondary ALK mutations, 31%; CNG, 13%; both secondary ALK mutations and CNG, 6% [27], and the remaining 50% are ALK non-dominant. Although much insight into the frequency and distribution of resistance mechanisms to crizotinib has been obtained, the resistance mechanisms to alectinib and ceritinib and their frequency and distribution remain to be fully elucidated.

In this section, we review the resistance mechanisms to ALK inhibitors identified in both clinical and pre-clinical settings.

**ALK Dominant**

Secondary mutations in the ALK gene are representative of ALK dominant resistance mechanisms. Choi et al. [28] first identified 2 secondary mutations in the ALK gene (C1156Y and L1196M) in a patient with ALK+ lung cancer who had progressed on crizotinib. Basic experiments confirmed that these mutations confer resistance to crizotinib: BA/F3 cells, murine interleukin-3-dependent pro-B cell lines expressing mutant forms of EML4-ALK with C1156Y and L1196M, were resistant to crizotinib, whereas the cells expressing primary EML4-ALK were successfully inhibited in a dose-dependent manner with crizotinib. Importantly, an analysis of the crystal structure of the kinase domain of ALK demonstrated that L1196 is located at the bottom of the ATP-binding pocket and that the L1196M mutation with a bulky side chain results in the interference of crizotinib binding to ALK. Intriguingly, the L1196M mutation corresponds to gatekeeper mutations in the BCR-ABL fusion gene (T315I) and in the EGFR gene (T790M) [29, 30]. As shown in Table 1, more than 10 mutations in the ALK gene have been so far identified to confer resistance to crizotinib: L1196M, G1269A, C1156Y, F1174L, I1171Tins, L1152R, S1206Y, I1171N/S/T [32, 34, 35], C1156Y [36], G1202R [37], and V1180L [34].

With regard to the secondary ALK mutations which confer resistance to alectinib, 2 mutations at codons 1171 and 1202 were identified [32–35]. 3 groups reported that the mutations at I1171 (I1171T, I1171N, and I1171S) confer resistance to alectinib, and the structural analysis revealed that disruption of a hydrogen bond between alectinib and E1167 by the I1171T mutation contributed to the destabilization of the alectinib complex with the mutant kinase [32, 34, 35]. Importantly, the mutations at codon 1171 also mediate crizotinib resistance, which can be overcome by ceritinib [32, 34]. Although V1180L also mediated a high resistance to alectinib in a cell line model, the mutation has yet to be identified in patients [34].

Friboulet et al. [36] examined 11 biopsied tumors in crizotinib-resistant patients, and secondary mutations including F1174C/V and G1202R were identified in 5 (45.5%) samples. Interestingly, F1174V and G1202R were found in 2 different sites in 1 patient, which suggests heterogeneity of resistance mechanisms in a single patient. Furthermore, it is remarkable that G1202R (which is postulated to be on the solvent-exposed region of the ALK kinase domain near the crizotinib-binding site) mediates resistance to crizotinib, alectinib, and ceritinib possibly by diminishing the binding affinity of ALK inhibitors to the mutant ALK through steric hindrance due to the presence of a large basic residue [36, 37]. In addition, a G1123S mutation in the ALK gene, which is known to induce resistance to TAE684, an ALK inhibitor in a neuroblastoma cell line, was identified to possibly mediate resistance to ceritinib [38, 39]. Codon 1123 is located in the glycine-rich loop, and mutations at codon 1123 appear to sterically block ATP binding and/or alter the dynamics of the glycine-rich loop, resulting in perturbation of the interactions with ALK inhibitors, which require a particular conformation of the loop for binding [39]. In vitro analyses demonstrated that C1156Y, I1151Tins, and L1152R also mediate resistance to ceritinib [36].

With regard to CNG of the fusion gene, 2 of 11 patients with ALK+ lung cancer who acquired resistance to crizotinib were reported to exhibit new onset ALK CNG, which may occur in combination with the ALK resistance mutations [40]. In contrast to this finding, ALK CNG has yet to be reported for alectinib- and ceritinib-resistant cancers.

Although brain metastases are sometimes called a 'sanctuary' in ALK+ lung cancer, recent evidence has shown the efficacy of ALK inhibitors, specifically alectinib, against brain metastases, which suggest that they are not necessarily a sanctuary [14, 16]. Detailed data regarding the efficacy of ALK inhibitors for brain metastases are not provided in this review article.

**ALK Non-Dominant**

As well as ALK secondary mutations, clinical and pre-clinical data have demonstrated newly identified resistance mechanisms to ALK inhibitors in an ALK non-dominant manner (Table 2). The data regarding resistance to crizotinib include EGFR mutation [40], KRAS mutation [40], activation of the ErbB family through phosphorylation [37], amplification of KIT [37], activation of the insulin-like growth factor 1 receptor (IGF-1R) pathway [41], EGFR ligands [42], hypoxia-induced epithelial-mesenchymal transition (EMT) [43], and autophagy [44].

<table>
<thead>
<tr>
<th>Crizotinib</th>
<th>Alectinib</th>
<th>Ceritinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>L1196M</td>
<td>I1171N/S/T</td>
<td>C1156Y</td>
</tr>
<tr>
<td>C1156Y</td>
<td>G1202R</td>
<td>F1174C/V</td>
</tr>
<tr>
<td>G1269A</td>
<td>V1180L</td>
<td>I1151Tins</td>
</tr>
<tr>
<td>F1174L</td>
<td>L1152R</td>
<td>G1202R</td>
</tr>
<tr>
<td>I1171T</td>
<td>G1202R</td>
<td>G1122S</td>
</tr>
<tr>
<td>L1206Y</td>
<td>V1171T</td>
<td>D1203N</td>
</tr>
<tr>
<td></td>
<td>V1180L</td>
<td>G1202R</td>
</tr>
</tbody>
</table>

Table 1. Secondary mutations in the ALK gene mediating resistance to crizotinib, alectinib, and ceritinib

---

Resistance Mechanisms to ALK Inhibitors and Strategies to Overcome Such Resistance

Table 2. Mechanisms conferring resistance to crizotinib, alectinib, and ceritinib

<table>
<thead>
<tr>
<th>Crizotinib resistance</th>
<th>EGFR mutation [40]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary mutations in the ALK gene [e.g. 21]</td>
<td></td>
</tr>
<tr>
<td>ALK CNG [40]</td>
<td></td>
</tr>
<tr>
<td>KRA S mutation [40]</td>
<td></td>
</tr>
<tr>
<td>activation of ErbB family [37]</td>
<td></td>
</tr>
<tr>
<td>amplification of KIT [37]</td>
<td></td>
</tr>
<tr>
<td>activation of IGF-1R pathway [41]</td>
<td></td>
</tr>
<tr>
<td>EGFR ligands [42]</td>
<td></td>
</tr>
<tr>
<td>hypoxia-induced EMT [43]</td>
<td></td>
</tr>
<tr>
<td>autophagy [44]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alectinib resistance</th>
<th>EGFR ligands [48]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secondary mutations in the ALK gene [32–35]</td>
<td></td>
</tr>
<tr>
<td>HGF/MET signaling pathway (MET amplification) [47–49]</td>
<td></td>
</tr>
<tr>
<td>hypoxia-induced EMT [43]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ceritinib resistance</th>
<th>Secondary mutations in the ALK gene [36, 38]</th>
</tr>
</thead>
</table>

With regard to the EGFR and KRAS mutations, Doebele et al. [40] investigated the resistance mechanisms to crizotinib in 11 of 14 patients with ALK+ lung cancer who experienced progressive disease on crizotinib. The EGFR and KRAS mutations were observed in 1 and 2 patients, respectively. An EGFR L858R mutation in 1 patient was found only in the post-crizotinib biopsy sample, and not in the initial biopsy sample, suggesting the involvement of the EGFR mutation in the acquired resistance to crizotinib. While 1 patient was shown to harbor the KRAS mutation prior to crizotinib treatment and have an intrinsic resistance to crizotinib, another KRAS mutation was identified only in re-biopsied sample without any evidence of a preexisting mutation in KRAS. In line with this report, a case with concomitant ALK rearrangement and KRAS mutation at codon 12 was intrinsically insensitive to crizotinib [45].

Cell line models and the investigation of patient-derived samples before and after crizotinib therapy showed the involvement of increased ErbB signaling through phosphorylation in the acquired resistance to crizotinib [37]. In 4 of 9 cases whose tumor samples were analyzed before and after crizotinib treatment, phospho-receptor tyrosine kinase arrays identified increased phospho-EGFR and phospho-ERBB3 levels in the resistant tumor compared with the corresponding sensitive tumor, which was confirmed by an immunoblotting assay using antibodies detecting phospho-EGFR and phospho-ERBB3. Intriguingly, in 1 patient with increased EGFR activation, a secondary ALK mutation was concomitantly identified, suggesting the possibility of heterogeneity of resistance mechanisms in a single patient. KIT amplification was also reported to induce resistance to crizotinib, which may require an increased expression of the KIT ligand stem cell factor [37]. In 2 patients with KIT amplification in post-crizotinib samples, increased phospho-EGFR and a secondary ALK mutation were identified, supporting the notion of multiple and diverse mechanisms of tyrosine kinase inhibitor (TKI) resistance within each individual patient.

Activation of the IGF-1R pathway was also reported to be involved in the resistance to crizotinib [41]. The experience of 1 ALK+ case successfully treated with IGF-1R-specific antibody and the following pre-clinical experiments showed the possible involvement of the activated IGF-1R and the adaptor insulin receptor substrate 1 pathway in the resistance to crizotinib and X-376, an ALK inhibitor. 4 of 5 tumor samples taken at the time of acquired resistance to crizotinib displayed increased levels of pIGF-1R, which indicates activation of the IGF-1R pathway. Other possible resistance mechanisms identified by pre-clinical investigation include EGFR ligands, EMT, and autophagy, whose significance in clinical settings remains unclear [42–44]. In addition, Giri et al. [46] identified novel mutations of 7 genes (CSMD3, CDKN2A, MAGI1, CREBBP, DOT1L, PBX1, and PRKDC) in a crizotinib-resistant tumor sample; however, their role in the acquired resistance to crizotinib was unclear due to the lack of data before the administration of crizotinib and the lack of basic experiments.

With regard to the involvement of alternate signaling pathways in the acquisition of resistance to next-generation ALK inhibitors, few reports exist thus far [43, 47–49]. In particular, the involvement of hepatocyte growth factor (HGF)/MET signaling pathway activation in the acquired resistance to alectinib has been demonstrated by several groups [47–49]. In our institution, we experienced an alectinib-resistant patient who was successfully treated with the crizotinib therapy, and intriguingly, MET amplification was observed in the re-biopsy sample of hepatic metastases after failure of alectinib, suggesting that MET amplification may act as an alternative signal, thereby conferring resistance to alectinib, and it may thus be overcome by crizotinib [47]. Furthermore, pre-clinical data by 2 groups demonstrated that HGF, a ligand of MET, induces resistance to alectinib, but not to crizotinib, via activation of MET signaling in vitro analyses [48, 49]. These findings suggest that activation of MET signaling may serve as a salvage signal after alectinib treatment, which is possibly not observed in crizotinib-resistance due to the high inhibitory activity of crizotinib against MET [19, 20]. As well as crizotinib-resistance, other groups have demonstrated that EGFR ligands and hypoxia-induced EMT confer resistance to alectinib [43, 48]. The resistance mechanism via the bypass track has yet to be reported in ceritinib-resistant patients or cells, which should therefore be investigated in clinical and pre-clinical settings.

### Strategies to Overcome the Resistance

As shown above, there is growing evidence for the existence of resistance mechanisms, and the establishment of individual treatment strategies to overcome these mechanisms is essential. In this section, the possible treatment options to overcome such resistance are discussed.
Next-Generation ALK Inhibitors

The efficacy of next-generation ALK inhibitors in crizotinib-resistant patients has been demonstrated by clinical and pre-clinical data [15, 16, 31, 36]. With regard to secondary ALK mutations, alectinib and ceritinib have been shown to be able to inhibit various types of mutated ALK including L1196M with lower IC50 than crizotinib [31, 36]. In clinical settings, the efficacy of ceritinib in patients with crizotinib-resistance via L1196M, G1209A, and 1151Tins (which is inconsistent with in vitro data as shown in [36]), S1206Y, and amplified ALK was confirmed; furthermore, ceritinib was effective in crizotinib-resistant patients without any ALK mutations or amplification [15]. Alectinib was also shown to be effective for crizotinib-resistant patients with a response rate of 55%, although resistance mechanisms to crizotinib were not mentioned in the trial [16]. However, given that G1202R is insensitive to crizotinib, alectinib, and ceritinib compared with other secondary mutations, sequential treatment with alectinib or ceritinib following failure of crizotinib therapy via G1202R is thought not to be able to overcome crizotinib resistance. In fact, this mutation was shown to induce resistance to alectinib and ceritinib in patients [33, 36]. Intriguingly, AP26113 and PF-06463922 were reported to harbor anti-tumor activity in cells with the G1202R mutation, demonstrating the possible use of these inhibitors after failure of crizotinib, alectinib, and ceritinib through G1202R [26, 50]. In addition, resistance to crizotinib by mutations at codons 1171 and 1174 may not be overcome by alectinib and ceritinib, respectively, given the findings that these mutations confer resistance to alectinib and ceritinib [32, 34–36]. Katayama et al. [34] demonstrated the efficacy of ceritinib in a patient with resistance to alectinib via the I1171T mutation. Experimental models confirmed this finding and showed that V1180L-mediated alectinib resistance is also overcome by ceritinib. Additionally, ceritinib was shown to overcome the resistance via the activated IGF-1R pathway because of its high inhibitory activity against IGF-1R as well as ALK [41]. With regard to the use of alectinib for ceritinib-resistance, alectinib was shown to be effective for resistance to ceritinib mediated via a G1123S mutation in the ALK gene [38].

HSP90 Inhibitors

HSP90 is a molecular chaperone that contributes to the correct folding of a number of newly synthesized polypeptides and unstable folded proteins and the prevention of their misaggregation [51]. Furthermore, EML4-ALK with and without the gatekeeper mutation was shown to be a client protein of the HSP90 chaperone [52]. Importantly, in vitro analyses showed that HSP90 inhibitors, such as ganetespib and 17-AAG, demonstrate anti-tumor activity for not only wild type EML4-ALK but also the mutated EML4-ALK with L1196M and F1174L mutations [52–54]. Clinically, objective responses to ganetespib and AUY922 were reported in patients with crizotinib-resistant ALK-rearranged NSCLC [54, 55]. Furthermore, 17-DMAG, one of the HSP90 inhibitors, was shown to be able to overcome alectinib-resistance that is mediated by receptor ligands, such as EGFR ligands and HGF [48]. As a result, it is possible that patients with resistance to ALK inhibitors may benefit from HSP90 inhibitors.

Inhibition of Alternative Bypass Signaling

The inhibition of alternative bypass signals, including KIT, MET, and IGF-1R, seems to play an important role in the treatment of patients with resistance to ALK inhibitors. For instance, cell-based analyses demonstrated that imatinib (KIT-TKI) and OSI-906 (IGF-1R-TKI) combined with crizotinib were reported to salvage bypass signal-induced resistance to crizotinib or X-376 via the KIT and IGF-1R pathways, respectively [37, 41]. With regard to resistance to crizotinib mediated by activation of the EGFR pathway, concurrent use of EGFR-TKIs with crizotinib is thought to be effective [37]. Additionally, AP26113, which is a dual inhibitor of the mutant activated forms of the ALK and EGFR genes, as well as TKI-resistant forms (including L1196M of the ALK gene and T790M of the EGFR gene) might harbor anti-tumor activity in patients with resistance to ALK inhibitors via the EGFR mutations. However, since these data were generated by in vitro analyses or conceptual studies only, they should be clarified in clinical settings. With regard to alectinib resistance via activation of the HGF/MET signaling pathway, Kogita et al. [49] showed that concurrent administration of a MET inhibitor with alectinib enhances the sensitivity to alectinib in cell-based models.

Crizotinib as a MET Inhibitor

As mentioned above, in vitro experiments demonstrated the association of the activation of the HGF/MET pathway with alectinib resistance; crizotinib as well as HSP90 inhibitors were shown to be able to overcome HGF-mediated resistance to alectinib [48, 49]. In fact, we experienced an ALK+ patient who was successfully treated with crizotinib, which was originally developed as a MET inhibitor, following the acquisition of resistance to alectinib via the possible mechanism of MET amplification [47]. These findings underline the significance of the activated HGF/MET pathway in alectinib resistance which can be overcome by inhibition of MET. Furthermore, crizotinib should be considered as a possible treatment option after acquisition of alectinib resistance through activation of the HGF/MET pathway.

Conclusion

We herein described the mechanisms of resistance to ALK inhibitors and the possible treatment strategies to overcome such resistance. Although ALK inhibitors are very effective for patients with ALK+ NSCLC, almost all patients eventually become resistant. Thus, it is a crucial and emergent issue to establish strategies to overcome the resistance according to each resistance mechanism. Importantly, a re-biopsy after the failure of ALK inhibitors should be encouraged to gain more insight into the resistance mechanisms and to properly treat patients who are resistant to ALK inhibitors.

Acknowledgement

We thank Brian Quinn for providing critical comments on the manuscript.
References


Disclosure Statement

Dr. Seto received honoraria from Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Novartis Pharma K.K., as well as research funding from Chugai Pharmaceutical Co., Ltd., Pfizer Japan K.K., and Novartis Pharma K.K.; Dr. Toyokawa received honoraria from Chugai Pharmaceutical Co. and Pfizer Japan Inc.
39 Gorre ME, Mohammed M, Ellwood K, Hsu N, Pau-quette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mu- 

30 Pao W, Miller VA, Politi KA, Ruely GJ, Sonnwar R, Zako- 
owski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is as- 

31 Kodama T, Tsukaguchi Y, Yoshida M, Kondo H, Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resis- 


33 Ignatiou Ou SH, Azada M, Hisagi DJ, Herman JM, 
\[\text{continued} \]

34 Sun X, Hua S, McNamara P, Mahmood S, Lockerman 
\[\text{continued} \]

35 Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, 
\[\text{continued} \]

36 Crystal AS, Michellys PY, Awad MM, Yanagitani N, 
\[\text{continued} \]

37 Takehara K, Sunami T, Mitani T, Japanese Tumor Mar- 

cer Group. Hsp90 inhibition in EML4-ALK lung cancer cells. On- 
\[\text{continued} \]

38 Tanimoto A, Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, 
\[\text{continued} \]

39 Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, 
\[\text{continued} \]

40 Lovly CM, McDonald NT, Chen H, Ortiz-Cuazan S, 
\[\text{continued} \]

41 Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke- 
\[\text{continued} \]

42 Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, 
\[\text{continued} \]

43 Katayama R, Briboulet L, Koike S, Lockerman EL, 
\[\text{continued} \]

44 Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, 
\[\text{continued} \]

45 Anai S, Suzuki K, Ijichi K, Harada T, Toyokawa G, 
\[\text{continued} \]

46 Giri S, Patel JK, Mahadevan D. Novel mutations in a 
\[\text{continued} \]

47 Gouji T, Takashi S, Mitsuhiro T, Yukito I. Crizotinib can 
\[\text{continued} \]

48 Tanimoto A, Yamada T, Nosaki J, Takeuchi S, Ebi H, 
\[\text{continued} \]

49 Kogita A, Togashy Y, Hayashi H, Banno E, Terashima 
\[\text{continued} \]

\[\text{continued} \]

51 Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of 
\[\text{continued} \]

52 Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Ri- 
\[\text{continued} \]

\[\text{continued} \]

54 Felip E, Carcereny B, Barlesi F, Gandhi L, Sequeira LE, 
\[\text{continued} \]

55 Lovly CM, McDonald NT, Chen H, Ortiz-Cuazan S, 
\[\text{continued} \]

56 Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, 
\[\text{continued} \]

57 Sasaki T, Okuda K, Zheng W, Butrynki J, Capelletti M, 
\[\text{continued} \]

58 Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, 
\[\text{continued} \]

59 Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, 
\[\text{continued} \]